Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New NIH director

This article was originally published in The Tan Sheet

Executive Summary

Elias Zerhouni, MD, confirmed as NIH director by the Senate in voice vote May 2. Zerhouni currently is executive vice dean of the Johns Hopkins University School of Medicine and chair of the department of radiology and radiological sciences; he obtained his medical degree from the University of Algeria in 1975 and emigrated the same year to the U.S. to train at JHU. As NIH director, one of Zerhouni's top priorities will be recruitment of individuals to fill the vacant directorships at several NIH institutes and centers; six lack permanent leadership...

You may also be interested in...

People In Brief

Zerhouni leaving NIH: National Institutes of Health Director Elias Zerhouni will leave his post at the end of October to pursue other opportunities, according to a Sept. 24 letter to NIH staff. He says he is "extremely fortunate to have led the agency that has been at the center of" a biomedical science revolution, "one that continues to have broad and profound implications for human health." Zerhouni says he will work with Health and Human Services Secretary Mike Leavitt to appoint his successor at NIH. A same-day NIH release details Zerhouni's achievements since his confirmation as director in 2002, including establishing ethics regulations to address outside consulting by NIH employees and starting public health research initiatives, such as the NIH Obesity Research Task Force (1"The Tan Sheet" May 6, 2002, In Brief and 2"The Tan Sheet" Aug. 29, 2005, p. 11)

WHO To Clean Up Data Integrity Failings

The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date. 

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts